Switzerland's BB Biotech Q1 net loss narrows amid portfolio rotation

Bb Biotech

24/04/2026 06:18

Overview

Switzerland biotech investor's Q1 net loss narrowed sharply year-over-year

Company's share price outperformed Nasdaq Biotechnology Index and discount to NAV narrowed

Portfolio expanded to 30 holdings, investment guidelines broadened to 20–50 positions

Outlook

Company says macroeconomic uncertainty and shifting geopolitics continue to influence equity markets

BB Biotech expects several portfolio holdings to reach clinical and regulatory milestones in 2026

Company is integrating AI-enabled analytics to enhance investment process and risk assessment

Result Drivers

PORTFOLIO REPOSITIONING - Co said active portfolio rotation, including eleven new investments and increased large-cap exposure, reshaped holdings and contributed to results

M&A IMPACT - Acquisition of Terns Pharmaceuticals by Merck contributed positively to quarterly performance

CLINICAL UPDATES - Some holdings saw negative share price reactions after clinical updates came in slightly below market expectations

Company press release: ID:nEQ8FSkNFa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-CHF 21 mln
Q1 Dividend
CHF 2.25


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for BB Biotech AG is CHF65.36, about 41.8% above its April 23 closing price of CHF46.10

The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 13 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)